人口药理动力学剂量反应分析血清,用环酸剂量后
Robert C Penland1, Magnus Åstrand2, David W Boulton3
1Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Boston, MA, USA. chris.penland@astrazeneca.com.
环环酸盐 (SZC) 通过降低血清,有效治疗高卡血症. 患者的年龄和基线含量等因素会影响反应,但不同患者群体不需要调整剂量.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 临床试验 临床试验
背景情况:
- 氧化环酸盐 (SZC) 是一种口服治疗高血症的药物.
- 它在肠道中选择性地结合 (K+),增加便的分泌.
研究的目的:
- 描述血清K+对SZC的群体药动力学 (PopPD) 反应.
- 估计患者因素对SZC疗效的影响.
- 比较SZC的维持剂量 (5克QOD与2.5克QD).
主要方法:
- 利用了来自七项II期和III期临床试验的综合数据.
- 采用半机械纵向混合效应模型与间接响应PK-PD建模.
- 进行了完整的共同变量建模,以评估影响EC50,安慰剂反应和Kaut.的因素.
主要成果:
- 分析包括2369名患者,25764名血清K+观察结果.
- 在5gQOD和2.5gQD维持剂量之间没有观察到血清K+减少的临床上有意义的差异.
- 较高的基线K +,晚年,较低的体重,较低的eGFR以及黑人/非洲裔美国人和亚洲种族与更大的SZC反应有关.
结论:
- PopPD模型充分描述了SZC在正和维护阶段对血清K+的影响.
- 对SZC反应的共变量影响很小.
- 根据评估的共同变量,不建议对SZC进行剂量调整.
更多相关视频
10:07High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
Dose-Response Relationship: Potency and Efficacy
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Time Course of Drug Effect
